Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BC3195 in Advanced Solid Tumors
NCT06548672Phase 1Recruiting
- Sponsor
- BioCity Biopharma
- Start
- Jun 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of BC3195 in head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), breast cancer and 8 more (2 arms), sponsored by BioCity Biopharma. Primary endpoints: Incidence of Dose Limiting Toxicities at 21 days, Maximum Tolerated Dose / Recommended Phase 2 Dose and 1 more. Started Jun 2024; status: recruiting.
02
Drugs
BC3195
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)breast cancernon-small cell lung cancer (NSCLC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT06548672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548672.